__________________________________________________________________________________

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________________________________________

FORM 6-K

__________________________________________________________________________________

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

December 1st, 2025

Commission File Number: 001-39777

__________________________________________________________________________________

NANOBIOTIX S.A.

(Translation of registrant’s name into English)

___________________________________________________________________________

60 rue de Wattignies 75012 Paris, France

(Address of principal executive offices)

__________________________________________________________________________________

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 1, 2025, Nanobiotix SA (the “Registrant”) provided notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them in accordance with the requirements of the EU Market Abuse Regulation (“MAR”), which are attached hereto as Exhibit 99.1.

EXHIBIT INDEX


Exhibit			Description
99.1			PDMR notifications pursuant to MAR, dated December 1, 2025 (French version)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANOBIOTIX S.A.

Date: December 1, 2025 By: Laurent Levy, Chairman of the Executive Board

Nanobiotix S.A. 6-K